BRAIN Biotech AG
BRAIN Biotech AG provides bio-based products and solutions in Germany, the United States, France, the Netherlands, and the United Kingdom. The company operates through two segments: BRAINBiocatalysts and BRAINBioIncubator. The BRAINBiocatalysts segment develops, produces, and distributes specialty enzymes, microorganisms, and ingredients. The BRAINBioIncubator segment encompasses a pipeline of re… Read more
BRAIN Biotech AG (BNN) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -2.326x
Based on the latest financial reports, BRAIN Biotech AG (BNN) has a cash flow conversion efficiency ratio of -2.326x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-4.28 Million) by net assets (€1.84 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
BRAIN Biotech AG - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how BRAIN Biotech AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
BRAIN Biotech AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BRAIN Biotech AG ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Profarma Distribuidora de Produtos Farmacêuticos S.A
SA:PFRM3
|
0.247x |
|
Alexanderwerk Aktiengesellschaft
F:ALXA
|
N/A |
|
Peoples Financial Corp
OTCQX:PFBX
|
0.010x |
|
Eusu Holdings
KO:000700
|
0.031x |
|
CM Hospitalar SA
SA:VVEO3
|
0.052x |
|
Guler Yatirim Holding AS
IS:GLRYH
|
0.065x |
|
NRX Pharmaceuticals Inc
NASDAQ:NRXP
|
0.112x |
|
Many Peaks Minerals Ltd
AU:MPK
|
-0.042x |
Annual Cash Flow Conversion Efficiency for BRAIN Biotech AG (2012–2025)
The table below shows the annual cash flow conversion efficiency of BRAIN Biotech AG from 2012 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | €1.84 Million | €-9.23 Million | -5.015x | -1843.65% |
| 2024-09-30 | €13.89 Million | €-3.58 Million | -0.258x | -40.78% |
| 2023-09-30 | €23.01 Million | €-4.22 Million | -0.183x | -322.69% |
| 2022-09-30 | €34.25 Million | €-1.49 Million | -0.043x | +53.57% |
| 2021-09-30 | €41.83 Million | €-3.91 Million | -0.093x | +48.79% |
| 2020-09-30 | €26.14 Million | €-4.77 Million | -0.182x | +7.80% |
| 2019-09-30 | €17.09 Million | €-3.38 Million | -0.198x | -11.84% |
| 2018-09-30 | €30.64 Million | €-5.42 Million | -0.177x | -45.48% |
| 2017-09-30 | €47.36 Million | €-5.76 Million | -0.122x | +62.31% |
| 2016-09-30 | €26.93 Million | €-8.68 Million | -0.322x | +54.88% |
| 2015-09-30 | €5.76 Million | €-4.11 Million | -0.715x | -153.56% |
| 2014-09-30 | €13.85 Million | €-3.90 Million | -0.282x | -2.26% |
| 2013-09-30 | €17.59 Million | €-4.85 Million | -0.276x | +43.22% |
| 2012-09-30 | €12.12 Million | €-5.89 Million | -0.485x | -- |